ОПТИМИЗАЦИЯ ТЕРАПИИ ВИРУС ИНДУЦИРОВАННЫХ ЗАБОЛЕВАНИЙ ГЛОТКИ

Abstract

Introduction. Viral infections of the upper respiratory tract represent the dominant etiological group
among acute respiratory diseases (ARD), accounting for 65–75% of cases in the working-age population. Within the
ARD structure, diseases of the pharynx—speci cally acute pharyngitis, tonsillitis, and stomatitis—are associated with a
pronounced local in ammatory response manifested by dysphagia, edema, and hyperemia of the mucosa, which leads
to a signi cant decrease in quality of life and an increase in the temporary disability index.
Objective. To conduct a randomized assessment of the clinical effi cacy and pharmacological safety of Debara-VM
spray (dequalinium chloride 1.25 mg/mL + lidocaine hydrochloride 1.0 mg/mL) compared with conventional therapy
within a strategy to optimize symptomatic treatment of virus-induced pharyngeal pathologies in working-age patients
(18–45 years).
Materials and Methods. A randomized, prospective, parallel-group clinical study included 100 patients (50 per group;
mean age 32.4 ± 7.2 years), randomized in a 1:1 ratio. Diagnoses included acute pharyngitis, tonsillitis, or stomatitis with
veri ed viral etiology (PCRdetection of respiratory viruses). Group 1 (main): Debara-VM spray, 3–6 administrations per
day, 2 doses per administration (maximum 1.2 mL/day) for 7 days. Group 2 (control): ibuprofen 400 mg three times daily
plus gargling with 0.05% chlorhexidine four times daily. Primary outcomes: dynamics of the pharyngoscopic score (scale 0–9 points: hyperemia, edema, exudates) and symptom severity (VAS) on days 1, 3, and 7. Secondary outcomes: ESR,
CRP, and SF-36. Results. In the main group, reduction of the pharyngoscopic score by day 3 was 65% (from 6.8 ± 1.4 to
2.4 ± 1.1; p < 0.001), and by day 7 — 92% (to 0.5 ± 0.7); remission was achieved in 88% of patients. In the control group,
reductions were 42% by day 3 (to 4.0 ± 1.2; p < 0.05) and 70% by day 7 (to 2.1 ± 1.0); remission occurred in 68% (betweengroup
diff erence p < 0.01). No adverse events were reported in either group.
Conclusions. Debara-VM spray is superior to conventional therapy in both the speed and degree of regression of
pharyngoscopic and symptomatic manifestations, providing optimization of outpatient treatment with minimal risks. It
is recommended as a rst-line option in the speci ed patient cohort.